INDIAN EQUITY MARKET OUTLOOK- 23 SEPTEMBER 2016 :Major Headlines of the day: • Wipro to acquire Zhonghsan Ma Er Daily Products • Sun Pharmaceuticals among bidders for Bayer’s dermatology brands • IOC eyes entire GSPC stake in Mundra LNG terminal
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,
Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More
Sun Pharma gains after USFDA approval:Sun Pharmaceutical Industries advanced almost a percent to Rs 841.75 on BSE after the company said it received US drug regulator's approval for abbreviated new drug application for generic version of Glumetza tablets.The company will announce Q1 results on 12 August 2016.
Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …
Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines